Case-Coulter Translational Research Partnership, with support provided by JobsOhio for the Cleveland Innovation District, awards $1.9 million in funding and support for promising biomedical engineering university technologies (Oct 12, 2021)
The Case-Coulter Translational Research Partnership (CCTRP) at Case Western Reserve University, with support from JobsOhio as part of the Cleveland Innovation District initiative, has announced more than $1.9 million in funding and support for 10 promising university-based biomedical technologies. The School of Medicine’s Council to Advance Human Health further supported two of these projects with an additional $300,000.

Neuros Medical Raises $38.5M in Series BB Funding for Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain (Jan 7, 2021)
Neuros Medical, Inc., a medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, announced today the close of a Series BB financing totaling $38.5 million. 

Case-Coulter Translational Research Partnership Awards $1.1 Million in Funding and Support for Promising Biomedical Engineering University Technologies (Dec 1, 2020)
The Case-Coulter Translational Research Partnership, which helps to commercialize projects by clinicians and biomedical engineering faculty that improve human health and well-being, has awarded more than $1.1 million in financial backing and other support for the 2020 round of funding. Please click on the linked article to learn more about the technologies.

Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award (Apr 2, 2020)
The EsoCheck™ Esophageal Cell Collection Device with Collect+Protect™ Technology, developed and marketed by its majority owned subsidiary Lucid Diagnostics Inc. (“Lucid”), was named a Silver winner of the 2020 Edison Best New Product Awards in the Medical/Dental category and Testing Solutions subcategory.

“After a thorough review, the Edison Awards judges recognize EsoCheck as a game-changing innovation standing out among the best new products and services launched in their category,” said Frank Bonafilia, Executive Director of the Edison Awards.

XaTek Inc. receives key FDA designation to aid commercialization of its ClotChip device (Mar 3, 2020)
XaTek Inc., a clinical-stage diagnostic device company based in Cleveland, said it has received Breakthrough Device designation from the U.S. Food and Drug Administration for its ClotChip technology.

The designation represents "a significant and distinguishing step in advancing" the portable blood-clotting sensor toward commercialization, XaTech said in a news release issued Tuesday, March 3. The FDA created the Breakthrough Devices Program in 2018 to speed up the development, assessment and review of technologies that "provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions."

Lucid Diagnostics receives Breakthrough Device Designation for its EsoGuard Esophageal DNA Test (Feb 11, 2020)
Lucid Diagnostics Inc. has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its EsoGuard™ Esophageal DNA Test on esophageal samples collected using its EsoCheck™ Cell Collection Device in a prevalent well-defined group of patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease (GERD).

The FDA Breakthrough Device Program was created to offer patients more timely access to breakthrough technologies which “provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions” by expediting their development, assessment and review through enhanced communications and more efficient and flexible clinical study design, including more favorable pre/post market data collection balance. Breakthrough Devices receive priority FDA review, and a bipartisan bill before Congress (H.R. 5333) seeks to require Medicare to temporarily cover all Breakthrough Devices for three years while determining permanent coverage.

Case-Coulter Translational Research Partnership Awards $1.1 Million in Funding and Support for Promising Biomedical Engineering University Technologies (Sept 19, 2019)
The Case-Coulter Translational Research Partnership, which helps to commercialize projects by clinicians and biomedical engineering faculty that improve human health and well-being, has awarded more than $1.1 million in financial backing and other support for the 2019 round of funding. Please click on the linked article to learn more about the technologies.

Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ (June 24, 2019)
Lucid Diagnostics has received 510(k) marketing clearance for its EsoCheck Cell Collection Device™ (“EsoCheck”), a Case-Coulter Technology, from the U.S. Food and Drug Administration (FDA). EsoCheck is a non-invasive cell collection device that is designed to sample cells from a targeted region of the esophagus in a five-minute office-based procedure, without the need for endoscopy. The patient swallows a vitamin pill-sized capsule containing a small inflatable balloon attached to a thin catheter. As the catheter is withdrawn, it swabs the target area for a sample of cells and protects that sample from contamination as the device is removed. The sampled cells can then be subjected to any commercially available diagnostic test. FDA determined that EsoCheck is substantially equivalent to legally marketed predicate devices for its indications for use, namely “the collection and retrieval of surface cells of the esophagus in the general population of adults, 22 years of age or older”.

NervGen Pharma Completes $10 Million Initial Public Offering (June 24, 2019)
NervGen Pharma Corp., a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering ("IPO") of its common shares and listing as a Tier 2 company on the TSX Venture Exchange ("TSX-V"). The IPO consisted of the issuance of 10,000,000 common shares of the Company at a price of $1.00 per share for gross proceeds of $10,000,000. NervGen's common shares are expected to commence trading on the TSX-V under the symbol "NGEN" on Friday, March 15, 2019. The net proceeds of the IPO will be directed primarily to advancing NervGen's lead compound NVG-291 toward clinical development for the treatment of spinal cord injuries. Additionally, the Company will advance the underlying patented protein tyrosine phosphatase sigma ("PTPσ") inhibitor technology for additional indications of nerve damage. The Company's patented PTPσ technology was developed in the laboratory of Dr. Jerry Silver, an SCI and regenerative medicine researcher and professor at Case Western Reserve University.

Tata doctors to organise screening for oral cancer patients at Kumbh Mela (January 11, 2019)
While people across the globe are flocking to Uttar Pradesh to participate in the Kumbh Mela that starts next week, several oncologists from the Tata Memorial Hospital have taken up the initiative to examine devotees at one of the biggest human gatherings for oral cancer. They've tied up with the UP government for the project, hoping to set a record for the world's biggest scanning of devotees for oral cancer with a Case-Coulter technology.

TRP 2019 Proposal Cycle Announced (January 11, 2019)
The 2019 Request for Applications (RFA) is now open. The Request for Applications is provided here. This is the 4th year of the third phase of Translational Research Partnership (TRP) between Case Western Reserve and the Wallace H. Coulter Foundation. The mission is to support collaborative translational research projects that address unmet or poorly met clinical needs. The TRP seeks to improve patient care and accelerate the delivery of healthcare technology from academia to the marketplace. An overarching goal of the program is to foster research and development work likely leading to commercially relevant translational technologies within a 3-5 year horizon.

Case-Coulter technology featured as one of top 10 medical breakthroughs of 2018! (December 6, 2018)
Anant Madabhushi is featured in a discussion of his LunIRIS and LunIOTx technologies, which have the potential to quickly and accurately diagnose predict which lung cancer patents benefit from different types of treatments, and also aid in diagnosis.

Case-Coulter Translational Research Partnership awards $1.1 million for promising university-based biomedical engineering technologies (Sept 20, 2018)
The Case-Coulter Translational Research Partnership, which helps to commercialize projects by clinicians and biomedical engineering faculty that improve human health and well-being, has awarded more than $1.1 million in financial backing and other support for the 2018 round of funding.

NervGen signs license agreement to develop therapies for spinal-cord injury (July 24, 2018)
Case Western Reserve University and NervGen Pharma Corp., based in Vancouver, have entered into an exclusive licensing agreement to research, develop and commercialize a patented technology with potential to bring new therapies for spinal-cord injury and other conditions associated with nerve damage.

XaTek Inc. raises $9.1 million in Series A capital (July 11, 2018)
XaTek Inc. recently raised $9.1 million in Series A capital to advance and test the device it's developing called ClotChip — a portable sensing system that can quickly assess the clotting ability of a person's blood. The funding will support the completion of XaTek's first commercial product, including clinical trials and filing for U.S. Food and Drug Administration clearance for uses in hemophilia and anticoagulation therapy by mid-2021, according to a news release.

SynthoPlate Licensed to Haima Therapeutics (May 30, 2018)
Case Western Reserve University and Cleveland-based biotechnology company Haima Therapeutics LLC have signed a two-year option to license a technology to prevent and treat bleeding complications from trauma, low platelet counts and surgery.

EsoCheck Licensed to Lucid Diagnostics (May 16, 2018)
Case Western Reserve University and Lucid Diagnostics have signed an exclusive license agreement to commercialize a Case-Coulter Translational Research supported technology that quickly and accurately detects Barrett’s Esophagus, the primary precursor of esophageal cancer. The technology, called EsoCheck, combines a non-invasive, cell-sampling device with highly accurate DNA biomarkers to detect the condition.

TRP 2018 Proposal Cycle Announced (January 9, 2018)
The 2018 Request for Applications (RFA) is now open. The Request for Applications is provided here. This is the 3rd year of the third phase of Translational Research Partnership (TRP) between Case Western Reserve and the Wallace H. Coulter Foundation. The mission is to support collaborative translational research projects that address unmet or poorly met clinical needs. The TRP seeks to improve patient care and accelerate the delivery of healthcare technology from academia to the marketplace. An overarching goal of the program is to foster research and development work likely leading to commercially relevant translational technologies within a 3-5 year horizon.

Coulter Program Director Awarded Crain's 40 Under 40 (November 20, 2017)
Steve Fening, the Director of the Case-Coulter Translational Research Partnership, was recently named as one of Crain's Cleveland Business 40 Under 40.

Case-Coulter Translational Research Partnership awards $1.1 million for promising university-based biomedical engineering technologies (November 15, 2017)
The Case-Coulter Translational Research Partnership, which helps to commercialize projects by clinicians and biomedical engineering faculty that improve human health and well-being, has awarded more than $1.1 million in financial backing and other support for the 2017 round of funding.

NueroRadVision wins Health-Tech Competition (April 27, 2017)
NeuroRadVision, a Case-Coulter Project, won first place in the collegiate division at the Medical Capital Innovation Competition in downtown Cleveland this week. Their proposal involved software that uses artificial intelligence and image analysis to allow doctors to easily tell the difference between cancerous and benign brain tumors. Prize: $6,000.

Medical Technology: Ohio's bio boom (April 5, 2017)
Featured on the front page of Nature, "Medical technology: Ohio's bio boom," The Wallace H. Coulter Foundation has teamed up with Case Western Reserve University — the leading patent-producing university in the state. 

The Sweet 16 Of Medtech Madness (March 21, 2017)
What do basketball and biomedical engineering have in common? They are both areas where universities compete. Most of you are well aware that we are in the midst of March Madness — the tournament determining the men’s and women’s NCAA Division I basketball champions. But, what you may not realize is that, just over a decade ago, nearly 100 universities with biomedical engineering programs were in competition to become translational research partners with the Coulter Foundation.

TRP 2017 Proposal Cycle Announced (January 6, 2017)
The 2017 Request for Applications (RFA) is now open. The Request for Applications is provided here. This is the 1st year of the third phase of Translational Research Partnership (TRP) between Case Western Reserve and the Wallace H. Coulter Foundation. The mission is to support collaborative translational research projects that address unmet or poorly met clinical needs. The TRP seeks to improve patient care and accelerate the delivery of healthcare technology from academia to the marketplace. An overarching goal of the program is to foster research and development work likely leading to commercially relevant translational technologies within a 3-5 year horizon.

ICBM Medical, a CCTRP Technology Based Startup Launched (December 12, 2016)
Case Western Reserve University and ICBM Medical Inc. signed a one-year option-to-license agreement to commercially advance a low-cost, rapid catalytic biomarker technology that improves patient screening and monitoring for a range of clinical conditions, from concussion to prostate cancer. Read full press release here.

XaTek, a CCTRP Technology Based Startup Launched (December 5, 2016)
Case Western Reserve University researchers have developed a portable sensor that can assess the clotting ability of a person’s blood 95 times faster than current methods—using only a single drop of blood. XaTek, a new Cleveland-based company, licensed the technology for the device—called ClotChip—with a goal of bringing it to market within the next three years. Read full press release here.

TRP 2016 Awards Announced (November 15, 2016)
The Case-Coulter Translational Research Partnership has announced more than $1 million in funding and support for the 2016 cycle. Four projects were selected for full program funding. Projects range from diagnostic and screening technologies to cancer therapeutics. Six pilot grants also were awarded for earlier-stage projects. Read full press release here.

CWRU Receives $500,000 State Grant for Technology Start-up Fund (November 10, 2016)
The Ohio Third Frontier Commission has awarded Case Western Reserve University a $500,000 grant for a campus-based translational research fund to help faculty researchers advance and commercialize their innovations. Read full press release here.

Hemex Health, a CCTRP Technology Startup Receives Prestigious Award (November 3, 2016)
A CCTRP team has won national recognition for a portable malaria detection device with the potential to transform diagnosis and treatment of the disease in developing countries. The team is one of four recipients of the U.S. Patent and Trademark Office’s Patent for Humanity Award in the category of medicine, and will be honored later this month at a White House ceremony. Earlier this year, this and another CCTRP technology were the basis of a new startup company, Hemex Health. Read full press release here.

Case Coulter Translational Research Partnership, University Hospitals offer new collaborative pilot award (October 11, 2016)
The Case Coulter Translational Research Partnership and University Hospitals are offering a collaborative pilot award opportunity to promote the development of new translational research projects between problem owners (clinicians) and solution providers (engineers). The target areas for funding are in the infectious disease domain. Read full press release here.

CCTRP Project Partners with Halyard Health (September 22, 2016)
What if eliminating physical pain was a matter of flipping a switch to block it? No drug needed. When it’s time to stop the block, just turn it off. Researchers at Case Western Reserve University hope to eventually treat chronic or acute pain by using energy-based neuromodulation technology. Read full press release here.